ABBV
Abbvie Inc. Health Care Pharmaceutical Preparations S&P 500Russell 3000
$294.89Close
$542.2BMarket cap
$195.99 – $294.8952-week range
Jan 30, 2027Next report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 86 · stronger than 86% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high at its 52-week high
- Accumulation up-day volume 1.9× down-day volume over 50 sessions
- Earnings growing EPS +285% year on year, faster than the quarter before (+331 pts)
Cautions
- Extended 4.6 ATR above its 50-day average
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 3.2%
price change
1mo
up 13.4%
price change
12-month return
up 32%
market up 11% ·
its own up 23%
F-score
7 / 9
Strong
Altman Z
2.91
Moderate risk
P/E
128.3×
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
up 2.5%
EBIT / enterprise value
Cheaper than
45%
of the market · around average
Revenue growth
up 9%
year on year
EPS growth
up 285%
latest quarter · +331 pts
Sales growth
—
latest quarter
ROE
—
return on equity
Free cash margin
up 29%
$17.8B FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
3.9×
Interest cover
5.2×EBIT / interest
Piotroski tests
- profitability slipped from last year
- issued more shares
- profitable on its assets
- generating cash from operations
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
- gross margin widened
- assets working harder
Trade setup
ATR%
2.2%
$6.40 a day · 2×ATR $282.09
RS
86 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.5×
vs 50-day average
Up/down volume
1.91
50 sessions
Implied move
—
no scheduled report
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$3.3B as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
Last reported
Oct 30, 2026
Results reaction
Oct 30, 2026+3% vs market2 sessions after results
Options
$33.5M27.3% IV · activity
Financials
- Gross 70%
- Net 7%
- Free cash 29%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $45.8B | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |
| Gross margin | 66% | 69% | 70% | 62% | 70% | 70% |
| Operating income | $11.4B | $17.9B | $18.1B | $12.8B | $9.1B | $15.1B |
| Net income | $4.6B | $11.5B | $11.8B | $4.9B | $4.3B | $4.2B |
| Net margin | 10% | 21% | 20% | 9% | 8% | 7% |
| Earnings per share | $2.76 | $6.50 | $6.66 | $2.74 | $2.41 | $2.38 |
| Free cash flow | $16.8B | $22.0B | $24.2B | $22.1B | $17.8B | $17.8B |
| Free cash margin | 37% | 39% | 42% | 41% | 32% | 29% |
| Cash | $8.4B | $9.7B | $9.2B | $12.8B | $5.5B | $5.2B |
| Long-term debt | $84.9B | $76.0B | $63.1B | $59.2B | $66.8B | $64.5B |
| Shareholders' equity | $13.1B | $15.4B | $17.3B | $10.4B | $3.3B | -$3.3B |
| Shares outstanding | 1.79bn | 1.80bn | 1.81bn | 1.82bn | 1.83bn | 1.84bn |
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $277 – $313 ±6.1% by Nov 27, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 27.3% priced · 20.8% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs less
Positioning
- Premium traded
- $33.5M calls $28.1M · puts $5.4M · latest session
- 0.19× -0.76 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls -4.34k · puts -605 past week
For options traders: ATM IV 27.3% (-3.7% 1w) · 1m ÷ 3m IV 1.05 · 25Δ skew 2.2 pts · Net GEX $76.4M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 3, 2026 | Quarterly ↗ | Jun 30, 2026 | 34d |
| May 8, 2026 | Quarterly ↗ | Mar 31, 2026 | 38d |
| Feb 20, 2026 | Annual ↗ | Dec 31, 2025 | 51d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 4, 2025 | Quarterly ↗ | Jun 30, 2025 | 35d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Feb 14, 2025 | Annual ↗ | Dec 31, 2024 | 45d |
| Nov 4, 2024 | Quarterly ↗ | Sep 30, 2024 | 35d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 3, 2024 | Quarterly ↗ | Mar 31, 2024 | 33d |
| Feb 20, 2024 | Annual ↗ | Dec 31, 2023 | 51d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 30, 2026 | Results ↗ |
| Oct 15, 2026 | Director or officer change ↗ |
| Oct 5, 2026 | Results ↗ |
| Sep 3, 2026 | Regulation FD ↗ |
| Aug 18, 2026 | Other events ↗ |
| Aug 5, 2026 | Other events ↗ |
| Jul 31, 2026 | Results ↗ |
| Jul 6, 2026 | Results ↗ |
| Jun 22, 2026 | Regulation FD ↗ |
| May 12, 2026 | Shareholder vote ↗ |
| Apr 29, 2026 | Results ↗ |
| Apr 3, 2026 | Results ↗ |